63
Participants
Start Date
May 6, 2019
Primary Completion Date
December 1, 2024
Study Completion Date
February 28, 2027
Pembrolizumab
Pre-Surgery: Pembrolizumab, one 200mg dose; Post-Surgery: Pembrolizumab, 200 mg every 3 weeks.
Wide Excision and Sentinel Lymph Node (SLN) Biopsy
Wide excision and SLN biopsy and pathologic assessment of tissue will be performed per standard of care.
Abramson Cancer Center of the University of Pennsylvania, Philadelphia
University of Louisville, Louisville
The University of Texas MD Anderson Cancer Center, Houston
Abramson Cancer Center at Penn Medicine
OTHER